Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is a Healthcare company (Biotechnology) with a market capitalization of $66M. The Maz Rating grades it against the other companies in its sector.
Atara Biotherapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.50, Atara Biotherapeutics, Inc. trades at 16.7x sales. Over the last twelve months it generated about $4M of revenue and a net loss of $10M. It runs a gross margin of 82.7%, an operating margin of -343.6% and a net margin of -368.6%. It shows return on equity of 38.8%, return on invested capital of -103.8% and a free cash flow yield of -19.6%. On the balance sheet: a debt-to-equity ratio of -0.25 and a current ratio of 1.72. Over the past 52 weeks the share price ranged from $3.92 to $19.15, with a beta of 0.09.
Atara Biotherapeutics, Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 4 Buy, 7 Hold and 2 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.